SMMNY (Siemens Healthineers AG) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Siemens Healthineers AG's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

Siemens Healthineers AG's long-term debt to total assets ratio increased from Sep. 2023 (0.01) to Sep. 2024 (0.01). It may suggest that Siemens Healthineers AG is progressively becoming more dependent on debt to grow their business.

Siemens Healthineers AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Siemens Healthineers AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siemens Healthineers AG LT-Debt-to-Total-Asset Chart

Siemens Healthineers AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Siemens Healthineers AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Siemens Healthineers AG LT-Debt-to-Total-Asset Calculation

Siemens Healthineers AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )	/	Total Assets (A: Sep. 2024 )
	=	569.367	/	51115.427
	=	0.01

Siemens Healthineers AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	569.367	/	51115.427
	=	0.01

Siemens Healthineers AG (OTCPK:SMMNY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Siemens Healthineers AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Siemens Healthineers AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SMMNY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SEMHF:USA 1SHL:Italy SHLd:UK 0PMJ:UK SHL:Germany SHL:Austria

Address

Siemensstr. 3, Forchheim, BY, DEU, 91301

Website

https://www.siemens-healthineers.com

Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2023) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (16% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (21%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. North America represents 41% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific including China the remainder.